Login to Your Account

American Association For Cancer Research

DOR's OrBec For Treating iGVHD Now On NDA Track

By Karen Pihl-Carey

Thursday, April 21, 2005
Despite missing the primary endpoint in a pivotal trial for orBec to treat intestinal graft-vs.-host disease (iGVHD), DOR BioPharma Inc. intends to file a new drug application before the end of the year. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription